Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2021 - 2025)

Gyre Therapeutics (GYRE) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$0.02 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) changed N/A to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.01 through Dec 2025, down 80.0% year-over-year, with the annual reading at $0.02 for FY2025, 60.0% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.02 at Gyre Therapeutics, down from $0.03 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.64 in Q2 2022, with the low at -$1.51 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.23, with a median of -$0.01 recorded in 2025.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 356.25% in 2022, while the deepest fall reached 100.0% in 2022.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.64 in 2021, then tumbled by 100.0% to -$1.28 in 2022, then decreased by 17.97% to -$1.51 in 2023, then surged by 100.66% to $0.01 in 2024, then crashed by 300.0% to -$0.02 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.02, $0.03, and $0.01 for Q4 2025, Q3 2025, and Q3 2024 respectively.